Company profile for Verastem Oncology

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

When it comes to combatting cancer, we realize there are no “one size fits all” treatment approaches. We understand that every cancer lives in an intricate and complex microenvironment, creating significant unmet needs which must be addressed. It’s why we remain open to new ideas and selectively pursue science with the potential to make a significant impact for physicians, patients and their caregivers. We are focusing o...
When it comes to combatting cancer, we realize there are no “one size fits all” treatment approaches. We understand that every cancer lives in an intricate and complex microenvironment, creating significant unmet needs which must be addressed. It’s why we remain open to new ideas and selectively pursue science with the potential to make a significant impact for physicians, patients and their caregivers. We are focusing on a portfolio of small molecule drugs inhibiting critical signaling pathways in cancer, including the phosphoinositide 3-kinase (PI3K) and focal adhesion kinase (FAK) pathways.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
117 Kendrick Street, Suite 500, Needham, Massachusetts 02494
Telephone
Telephone
781-465-7936
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251125239573/en/Verastem-Oncology-to-Present-at-the-8th-Annual-Evercore-Healthcare-Conference

BUSINESSWIRE
25 Nov 2025

https://www.businesswire.com/news/home/20251113480267/en/Verastem-Oncology-Announces-Pricing-of-%2490-Million-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants

BUSINESSWIRE
14 Nov 2025

https://www.businesswire.com/news/home/20251113430863/en/Verastem-Oncology-Announces-Proposed-Public-Offering-of-Common-Stock

BUSINESSWIRE
13 Nov 2025

https://www.businesswire.com/news/home/20251104061050/en/Verastem-Oncology-to-Present-at-Upcoming-Investor-Conferences

BUSINESS WIRE
05 Nov 2025

https://www.businesswire.com/news/home/20251104228194/en/Verastem-Oncology-Reports-Third-Quarter-2025-Financial-Results-and-Highlights-Recent-Business-Updates

BUSINESSWIRE
04 Nov 2025

https://www.businesswire.com/news/home/20251023365893/en/Verastem-Oncology-to-Report-Third-Quarter-2025-Financial-Results-on-November-4-2025

BUSINESSWIRE
23 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty